X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Neurology Product Name: AD101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Societal CDMO
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Neurology Product Name: AD101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Societal CDMO
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 01, 2022
Details:
AD101 was initially discovered in phenotypic testing of animal models of learning and memory. It also improved learning and memory in models dependent on Aβ and tau while reducing the accumulation of both biomarkers in these animals.
Lead Product(s): AD101
Therapeutic Area: Neurology Product Name: AD101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
